EquipmentShare.com (NASDAQ:EQPT) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) Financial Contrast

EquipmentShare.com (NASDAQ:EQPT) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Earnings and Valuation

This table compares EquipmentShare.com and Cyclacel Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EquipmentShare.com	$4.38 billion	0.87	$40.00 million	$0.31	48.68
Cyclacel Pharmaceuticals	$750,000.00	6.25	-$3.00 million	($3.64)	-0.23

EquipmentShare.com has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than EquipmentShare.com, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for EquipmentShare.com and Cyclacel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EquipmentShare.com	1	5	6	0	2.42
Cyclacel Pharmaceuticals	1	0	0	0	1.00

EquipmentShare.com presently has a consensus price target of $34.33, suggesting a potential upside of 127.52%. Given EquipmentShare.com’s stronger consensus rating and higher probable upside, equities research analysts clearly believe EquipmentShare.com is more favorable than Cyclacel Pharmaceuticals.

Institutional & Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 32.8% of EquipmentShare.com shares are owned by company insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares EquipmentShare.com and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EquipmentShare.com	N/A	N/A	N/A
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Summary

EquipmentShare.com beats Cyclacel Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About EquipmentShare.com

EquipmentShare.com Inc. provides integrated, full-service construction solutions across equipment rental, sales and technology. EquipmentShare.com Inc. is based in Columbia, Missouri.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.